{
  "name": "ClinicalIntelPulse",
  "description": "Pharmaceutical pipeline and clinical trial intelligence API. Synthesizes 400,000+ registered trials from ClinicalTrials.gov with FDA OpenFDA, PubMed, and real-time news. 10 endpoints: pipeline scans, FDA/EMA approval probability, pharma sponsor competitive intelligence, full disease landscape reports (replaces Evaluate Pharma), clinical trial deep dives, drug mechanism mapping, global WHO ICTRP trial coverage, trial failure analysis, patient trial finder, and biotech M&A deal signals. Pay-per-query via x402 micropayments on Base.",
  "url": "https://clinicalintelpulse.vercel.app",
  "version": "1.0.0",
  "capabilities": [
    "clinical-trial-intelligence", "pharmaceutical-pipeline-analysis", "fda-approval-probability",
    "ema-approval-tracking", "pdufa-calendar", "sponsor-competitive-intelligence",
    "disease-landscape-analysis", "drug-mechanism-mapping", "global-trial-coverage",
    "who-ictrp-registries", "trial-failure-analysis", "patient-trial-finder",
    "biotech-ma-signals", "licensing-intelligence", "pubmed-synthesis",
    "oncology-pipeline", "rare-disease-pipeline", "neurology-pipeline", "cardiovascular-pipeline"
  ],
  "data_sources": [
    "ClinicalTrials.gov REST API v2 — 400,000+ trials (free, no key)",
    "FDA OpenFDA API — NDA/BLA approvals, adverse events (free, no key)",
    "PubMed NCBI E-utilities — 35M+ papers (free, optional key)",
    "WHO ICTRP registries — ChiCTR, CTRI, UMIN, REBEC, ANZCTR, KCT, DRKS + 10 more (via synthesis)",
    "EMA EPAR — European Public Assessment Reports (via synthesis)",
    "PDUFA calendar — FDA action dates (via synthesis)",
    "BioPharma M&A deal data (via synthesis)"
  ],
  "coverage": {
    "trials": "400,000+ ClinicalTrials.gov; 200,000+ additional via WHO ICTRP",
    "diseases": "All — oncology, neurology, cardiology, rare diseases, infectious diseases, metabolic, immunology",
    "countries": "190+",
    "languages": ["en", "es", "fr", "de", "ja", "zh", "ko", "pt", "ar", "hi"],
    "regulatory_agencies": ["FDA", "EMA", "PMDA (Japan)", "NMPA (China)", "CDSCO (India)", "TGA (Australia)", "ANVISA (Brazil)", "WHO Prequalification"]
  },
  "payment": {
    "protocol": "x402",
    "network": "eip155:8453",
    "asset": "USDC",
    "contract": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
    "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc"
  },
  "endpoints": [
    { "path": "/api/clinical/pipeline-scan", "method": "GET", "description": "Phase 2/3 trial count, sponsor landscape, geographic distribution, mechanism breakdown for any disease.", "parameters": [{"name":"condition"},{"name":"phase","options":"phase2|phase3|both"},{"name":"lang"}], "price_usd": 0.15, "payment_required": true },
    { "path": "/api/clinical/approval-outlook", "method": "GET", "description": "FDA/EMA approval probability — PDUFA calendar, success rates, regulatory designations.", "parameters": [{"name":"condition"},{"name":"horizon","options":"12m|18m|24m"},{"name":"agency","options":"FDA|EMA|both"},{"name":"lang"}], "price_usd": 0.25, "payment_required": true },
    { "path": "/api/clinical/sponsor-intel", "method": "GET", "description": "Full pipeline by phase, FDA approvals, Phase 3 assets, partnerships for any pharma/biotech company.", "parameters": [{"name":"sponsor"},{"name":"focus","options":"pipeline|approvals|deals|all"},{"name":"lang"}], "price_usd": 0.20, "payment_required": true },
    { "path": "/api/clinical/disease-landscape", "method": "GET", "description": "Comprehensive disease brief — approved drugs, mechanism gaps, pipeline map, PDUFA, deals, opportunity score 0-100. Replaces Evaluate Pharma.", "parameters": [{"name":"condition"},{"name":"depth","options":"standard|deep"},{"name":"lang"}], "price_usd": 0.35, "payment_required": true },
    { "path": "/api/clinical/trial-brief", "method": "GET", "description": "Full design, endpoints, eligibility, enrollment, outcome for any trial by NCT ID.", "parameters": [{"name":"nct_id","required":true},{"name":"lang"}], "price_usd": 0.10, "payment_required": true },
    { "path": "/api/clinical/mechanism-map", "method": "GET", "description": "Approved MOAs, pipeline targets, first-in-class opportunities, white spaces, modality breakdown.", "parameters": [{"name":"condition"},{"name":"mechanism","required":false},{"name":"lang"}], "price_usd": 0.20, "payment_required": true },
    { "path": "/api/clinical/global-trials", "method": "GET", "description": "WHO ICTRP registry coverage — ChiCTR, CTRI, UMIN, REBEC, ANZCTR, KCT + regional regulatory landscape.", "parameters": [{"name":"condition"},{"name":"region","options":"global|africa|asia|europe|latin-america|middle-east|north-america"},{"name":"lang"}], "price_usd": 0.15, "payment_required": true },
    { "path": "/api/clinical/failure-analysis", "method": "GET", "description": "Phase 2→3 and Phase 3→approval success rates, failure taxonomy, named failed trials, lessons for new programs.", "parameters": [{"name":"condition"},{"name":"lang"}], "price_usd": 0.20, "payment_required": true },
    { "path": "/api/clinical/patient-finder", "method": "GET", "description": "Plain-language recruiting trial finder for patients — accessible eligibility, application guide, advocacy resources.", "parameters": [{"name":"condition"},{"name":"country","required":false},{"name":"phase","options":"phase2|phase3|any"},{"name":"lang"}], "price_usd": 0.10, "payment_required": true },
    { "path": "/api/clinical/deal-signal", "method": "GET", "description": "Biotech M&A signals — acquisition targets with deal values, recent comps, likely acquirers, timing signals.", "parameters": [{"name":"condition"},{"name":"deal_type","options":"acquisition|licensing|both"},{"name":"stage","options":"phase2|phase3|both"},{"name":"lang"}], "price_usd": 0.35, "payment_required": true }
  ],
  "openapi": "https://clinicalintelpulse.vercel.app/openapi.json",
  "llms_txt": "https://clinicalintelpulse.vercel.app/llms.txt",
  "contact": "info@theaslangroupllc.com",
  "operator": "The Aslan Group LLC"
}